SeaSpine to Report Third Quarter 2021 Financial Results on October 28, 2021

Rhea-AI Summary

SeaSpine Holdings Corporation (NASDAQ: SPNE) has announced that it will release its third quarter financial results post-market on October 28, 2021. The management team will host a conference call and webcast at 1:30 pm PT / 4:30 pm ET. Interested parties can listen to the call by dialing in or visiting the company’s website. SeaSpine specializes in surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implants designed to enhance surgical outcomes for spine procedures.

Positive

• Scheduled release of third quarter financial results can provide insight into company's performance.
• Company's strong portfolio in orthobiologics and spinal implants may contribute to future growth.

Negative

• None.

CARLSBAD, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Thursday, October 28, 2021. Members of the Company’s management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 6699691. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic, and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants, software and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact
Hunter Cabi
904-304-9505
ir@seaspine.com

FAQ

When will SeaSpine release its third quarter financial results?

SeaSpine will release its third quarter financial results after the market closes on October 28, 2021.

What time is the SeaSpine conference call scheduled?

The conference call is scheduled to begin at 1:30 PM PT / 4:30 PM ET.

How can I listen to the SeaSpine conference call?

You can listen to the conference call by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, or by visiting the Investors section of SeaSpine's website.

What products does SeaSpine offer?

SeaSpine offers a comprehensive portfolio of orthobiologics, spinal implants, and a market-leading surgical navigation system for spinal disorders.